DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

What Are the Potential Strengths and Weaknesses of Key Newly Launched and Emerging Therapies for Schizophrenia?

What Are the Potential Strengths and Weaknesses of Key Newly Launched and Emerging Therapies for Schizophrenia?

In the latest white paper from DRG, we provide a snapshot of the strengths and weaknesses of the key newly launched and late-phase emerging therapies for schizophrenia, to highlight the potential threats these therapies offer to current treatments as well as the remaining drug development opportunities in this space.

Therapies covered in this white paper:

  • Vraylar/Reagila (cariprazine)
  • Rexulti (brexpiprazole)
  • Aristada (aripirazole lauroxil long-acting depot)
  • Invega Trinza/Trevicta (paliperidone palmitate three-month depot)
  • Lu-AF35700
  • ALKS-3831
  • Lumateperone
  • Pimavanserin
  • RBP-7000
  • MIN-101